The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial,Emerging Microbes & Infections

当前位置： X-MOL 学术 › Emerg. Microbes Infect. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial
Emerging Microbes & Infections ( IF 13.2 ) Pub Date : 2024-02-29 , DOI: 10.1080/22221751.2024.2320913
Chunhua Zhou _{1,

2} , Yuanzheng Qiu ₃ , Jianxin Wang _{1,

2} , Xiang Zhong ₃ , Xiufang Zhu ₁ , Xiaojing Huang ₁ , Lan Yang ₁ , Qiaolei Ji ₃ , Feifei Zhou ₃ , Shunquan Wu ₃ , Mengjie Yang ₄ , Jing Zhang ₄ , Kaili Liu ₃ , Li Ji ₃ , Hanyu Yang ₃ , Chunlei Li ₃ , Yuanyuan Zhao ₁

Affiliation

Continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enhanced transmissibility, significant immune escape, and waning immunity call for booster vacc...

更新日期：2024-03-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>